BioSpace News Archive

GT Biopharma, Inc. announced highlights of an accepted abstract titled, “B7H3-Targeted Tri-specific Killer Engagers deliver IL-15 to NK cells but not T cells, and specifically targets solid tumors as a pan-tumor antigen strategy mediated through NK cells,” for poster presentation both virtually at the European Society for Medical Oncology Congress 2022 being held at the Paris Expo Porte de Versailles from September 9-13, in Paris, France.

Natera, Inc. today announced new data on its personalized and tumor-informed molecular residual disease (MRD) test Signatera™, at the 2022 European Society for Medical Oncology (ESMO) World Congress, taking place September 9-13 in Paris, France.

SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approval for OncoSeek® Multi-Cancer Detection Test and is now ready to launch this test in European Union and other countries that recognize CE mark.

AGAE Technologies, LLC, an Oregon-based leading specialty green chemical and biotech company, has discovered how to use selected strains and media under optimized fermentation conditions to achieve record-high yields of rhamnolipids at its lowest production cost.

Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to announce that Dr Valérie Méresse Naegelen,

Humanigen, Inc. (Nasdaq: HGEN), Humanigen Australia Pty Ltd, (“Humanigen”) and the South Australian Health and Medical Research Institute (“SAHMRI”) today announced an expansion of the ongoing development Precision Approach to Chronic Myelomonocytic Leukemia (“PREACH-M”) study of lenzilumab in chronic myelomonocytic leukemia (“CMML”), a rare blood cancer, in patients with NRAS, KRAS, and CBL genetic mutations.

IMFINZI ® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, is pleased to announce the appointment of Matvey Lukashev, PhD, as the Company’s Vice President, Research and Preclinical Development.

Metagenomics is defined as the extensive study of various types of genetic material recovered directly from environmental samples, which is further used for many purposes such as identification of a microbial species, classification of microorganisms, and understanding their importance on the planet dating back to their origin.

The recent research studies predict that the global pharmacovigilance market will record a stellar compound annual growth rate of 10.5 % over the forecast period of 2022 to 2030.